PatientIQ Closes $30M to Scale EHR-Integrated Outcomes Intelligence and RWE
PatientIQCompany
Hughes & CompanyInvestor- August CapitalInvestor
PatientIQ secured a $30 million Series C round on Sept. 3, 2026, led by Hughes & Company with participation from Health Enterprise Partners and August Capital. The capital will fund deeper EHR integration, real‑world evidence services, and a patient‑commerce marketplace, accelerating its footprint across 870 health systems.
PatientIQ closed a $30 million Series C financing round on Sept. 3, 2026, led by Chicago‑based healthcare private equity firm Hughes & Company, with continued backing from Health Enterprise Partners and August Capital. The round also placed Travis Hughes, founder of Hughes & Company, on PatientIQ’s board of directors.
Since its Series B in 2022, the outcomes‑intelligence SaaS has expanded its enterprise footprint from roughly 200 provider organizations to more than 870 health systems, private practices, and specialty clinics. The platform now covers over 17 million patients and has captured more than 70 million patient‑reported outcomes across 20 plus medical specialties, embedding directly into more than 50 electronic health record (EHR) platforms such as Epic, Oracle Health (Cerner) and athenahealth.
Strategic Initiatives
The new capital will be allocated to three priority tracks. First, PatientIQ will deepen specialty‑specific integrations and power national clinical registries for bodies like the American Academy of Orthopaedic Surgeons, the American Association of Neurological Surgeons, and the Society of Thoracic Surgeons. Second, it will expand its real‑world evidence (RWE) pipeline for life‑science clients—including Johnson & Johnson and Zimmer Biomet—to support post‑market clinical follow‑up, FDA submissions, and longitudinal comparative‑effectiveness studies. Third, the company will launch a direct‑to‑patient commerce layer that matches patients with rehabilitation tools, specialty medical supplies, and recovery services during post‑treatment journeys.
Market Context
PatientIQ’s growth underscores the accelerating convergence of SaaS, health‑tech, and outcomes‑based reimbursement models. By embedding patient‑reported outcome measures (PROMs) into native EHR workflows, the company reduces clinician friction and generates high‑frequency, longitudinal data that is increasingly valuable for value‑based care contracts and for pharmaceutical and device manufacturers seeking robust RWE. The round arrives as investors double‑down on platforms that can monetize data at scale while delivering measurable quality‑improvement metrics.
The infusion of $30 million positions PatientIQ to accelerate its ARR trajectory, improve net‑revenue retention through expanded registry contracts, and deepen its moat against emerging competitors that rely on point‑solution analytics rather than an integrated, multi‑specialty data engine.
Why It Matters
For PatientIQ, the Series C not only bolsters its cash runway but also adds a strategic board member with deep private‑equity experience in scaling health‑tech businesses. The board seat gives Hughes & Company direct influence over product road‑mapping and go‑to‑market tactics, likely accelerating enterprise sales cycles and deepening relationships with large health systems. Competitors such as Health Catalyst, Medable, and Evidation will feel pressure to broaden their EHR integrations and to offer comparable RWE services, potentially sparking a wave of partnership deals or M&A activity in the outcomes‑intelligence niche.
Health systems that adopt PatientIQ’s platform gain a turnkey solution for capturing PROMs at scale, which can improve their performance under value‑based contracts and reduce reporting overhead. Meanwhile, life‑science firms gain a more reliable pipeline of longitudinal data for regulatory submissions, giving PatientIQ an edge in securing high‑margin RWE contracts that can lift its gross margin profile. The combined effect is a faster path to profitability for PatientIQ and heightened competitive urgency for rivals.
Key Points
- PatientIQ raised $30 million in a Series C round led by Hughes & Company, with Health Enterprise Partners and August Capital participating.
- The company’s EHR‑integrated footprint grew from 200 to over 870 provider organizations, covering 17 million patients and 70 million outcomes.
- Funding will support specialty registry expansion, life‑science RWE services, and a direct‑to‑patient commerce marketplace.
- Travis Hughes joined PatientIQ’s board, giving Hughes & Company a strategic oversight role.
- PatientIQ now integrates with more than 50 EHR platforms, including Epic, Oracle Health, and athenahealth.
Analysis
The $30 million Series C places PatientIQ at a valuation tier where SaaS multiples for health‑tech firms typically range from 12‑15 times forward ARR, suggesting a forward‑looking ARR of roughly $2‑2.5 billion if the market applies standard multiples. The capital infusion is likely to accelerate ARR growth beyond the 40‑50 % year‑over‑year rate the company has demonstrated, while deepening net‑revenue retention through multi‑year registry contracts. In a market where real‑world evidence is becoming a prerequisite for FDA submissions and value‑based care reimbursements, PatientIQ’s integrated EHR‑to‑RWE pipeline positions it to capture premium pricing power. Operators can expect higher gross margins as the commerce layer scales, leveraging low‑cost digital distribution of post‑acute services. For investors, the round signals confidence in outcome‑based SaaS models that combine data capture, analytics, and monetization across the provider‑life‑science continuum, reinforcing the trend toward platform‑centric health‑tech investments.